概要
Tutorials: October 26*
Tutorial #1- Plain Language Labeling: Implementing Health Canada's Guidance for Industry
Tutorial #2- Strategies for Efficient Submission Preparation
*Tutorials require registration and are an additional fee
Meeting: October 27-28
A New Era in Regulatory Affairs - Building Capabilities to Support Innovation, Transparency, Quality and Safety of Health Products in Canada
As the Canadian health care system continues to evolve, the need for transparency is playing an important role in the development and management of new and existing medicines and devices. Numerous stakeholders are working to build regulatory capabilities that will help to promote innovation and to maintain high standards of quality and safety of important therapies and medicines in Canada.
The DIA Annual Canadian Meeting 2015 will bring together key thought leaders and experts, representing various stakeholders, to explore what this new era of regulatory affairs means to the Canadian health care and biopharmaceutical industries.
This year’s meeting will feature plenary sessions, multi-track breakout sessions, networking opportunities, tutorials and tabletop exhibiting opportunities.
プログラム委員会
-
Karen Feltmate President
Redstone Health Group, Inc., Canada -
Matthew Ryan Senior Policy Analyst; Policy, Planning and International Affairs Directorate
Health Canada, Canada -
Marilena Bassi, MA Senior Executive Director, Therapeutic Products Directorate
Health Canada, Canada -
Rocelyn DelCarmen Director, Regulatory Affairs and Quality Assurance
Astrazeneca Canada Inc., Canada -
Maggie Graham Senior Policy Analyst, Natural and Non-Prescription Health Products Directorate
Health Canada, Canada -
Vratislav Hadrava, MD, PHD Vice President and Medical Director, Global Innovative Products
Pfizer Canada, Inc., Canada -
Ljubica Ivanisevic, PHD Scientific Evaluator
Health Canada, Canada -
Chanez Narimene Kebache, MBA Director, Global Product Safety & Pharmacovigilance
Canopy Growth Corporation, Canada -
Marc Poitras, PHD, MBA Scientific Manager, Marketed Pharmaceuticals and Medical Devices Bureau
Health Canada, Canada
